Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.

Détails

ID Serval
serval:BIB_FCD994965646
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Périodique
European heart journal. Cardiovascular pharmacotherapy
Auteur(s)
Degrauwe S., Roffi M., Lauriers N., Muller O., Masci P.G., Valgimigli M., Iglesias J.F.
ISSN
2055-6845 (Electronic)
Statut éditorial
Publié
Date de publication
01/07/2019
Peer-reviewed
Oui
Volume
5
Numéro
3
Pages
158-163
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Recent evidence demonstrates that intravenous morphine significantly reduces absorption and delays onset of action of oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). We aimed to assess the influence of intravenous fentanyl compared with morphine on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients undergoing pPCI for STEMI.
Single-centre, prospective, open-label, randomized controlled study that will randomly assign in a 1:1 ratio patients with STEMI undergoing pPCI to receive intravenous fentanyl or morphine following a pre-hospital 180-mg loading dose of ticagrelor (ClinicalTrials.gov Identifier: NCT02531165). Pharmacokinetic and pharmacodynamic analyses will be performed at baseline and 1, 2, 4, 6, and 12 h post-loading dose. Pharmacodynamic assessments will include P2Y12 reaction units (PRU) measured by VerifyNow P2Y12. Pharmacokinetic assessments include determination of maximal observed plasma concentrations, time for maximal plasma concentration, and area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) for ticagrelor and AR-C124910XX. The primary endpoint is platelet reactivity assessed by PRU at 2 h post ticagrelor loading dose.
PERSEUS will provide randomized data regarding the impact of fentanyl administration, in patients with STEMI undergoing pPCI, on platelet inhibition and ticagrelor absorption and total exposure.
Mots-clé
Fentanyl, Platelet inhibition, ST-segment elevation myocardial infarction, Ticagrelor
Pubmed
Création de la notice
20/08/2018 13:58
Dernière modification de la notice
21/08/2019 6:36
Données d'usage